217 related articles for article (PubMed ID: 22713131)
1. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.
Guo X; Zhao Z; Xie J; Cai Q; Zhang X; Peng L; Gao Z
Virol J; 2012 Jun; 9():123. PubMed ID: 22713131
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H
J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses.
Guo X; Yang G; Yuan J; Ruan P; Zhang M; Chen X; Zhou B
PLoS One; 2013; 8(10):e77911. PubMed ID: 24147097
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
Huang CF; Yeh ML; Hsieh MH; Hsieh MY; Lin ZY; Chen SC; Wang LY; Huang JF; Juo SH; Lin YC; Dai CY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2013 Sep; 28(9):1515-20. PubMed ID: 23560893
[TBL] [Abstract][Full Text] [Related]
6. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
8. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
Shi KQ; Liu WY; Lin XF; Fan YC; Chen YP; Zheng MH
Gene; 2012 Oct; 507(1):27-35. PubMed ID: 22842190
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
11. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population.
Dong ZX; Zhou HJ; Xiang XG; Guo SM; Zhuang Y; Zhao GD; Xie Q
J Dig Dis; 2015 Feb; 16(2):90-7. PubMed ID: 25312023
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
[TBL] [Abstract][Full Text] [Related]
14. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
Garcia RF; Moreira S; de Araújo Ramos AL; Ferreira LE; de Mattos AA; Tovo CV; Nader LA; Ramos JA; Rondinelli E; de Jesus Dominici A; Garcia CE; de Souza Leite Pinho M; Brandão-Mello CE; Villela-Nogueira CA; de França PH
World J Gastroenterol; 2013 Nov; 19(42):7399-404. PubMed ID: 24259970
[TBL] [Abstract][Full Text] [Related]
16. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
Jung YK; Kim JH; Ahn SM; Yang JW; Park SJ; Kim JW; Yeon JE; Kwon OS; Kim YS; Choi DJ; Kim JH; Byun KS
J Clin Gastroenterol; 2013 Aug; 47(7):644-50. PubMed ID: 23442843
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the genetic variation in interleukin 28B and response to antiviral therapy in patients with chronic hepatitis C.
Xie JQ; Guo XY; Zhang XH; Lin BL; Xie DY; Gao ZL; Wang GS; Zhao ZX
Chin Med J (Engl); 2012 Jul; 125(13):2334-8. PubMed ID: 22882858
[TBL] [Abstract][Full Text] [Related]
18. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
[TBL] [Abstract][Full Text] [Related]
19. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
[TBL] [Abstract][Full Text] [Related]
20. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
